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Abstract
Identifying the viability of protein targets is one of the preliminary steps of drug discovery. Determining the ability of a
protein to bind drugs in order to modulate its function, termed the druggability, requires a non-trivial amount of time and
resources. Inability to properly measure druggability has accounted for a significant portion of failures in drug discovery.
This problem is only further exacerbated by the large sample space of proteins involved in human diseases. With these barriers, the druggability space within the human proteome remains unexplored and has made it difficult to develop drugs for
numerous diseases. Hence, we present a new feature developed in eFindSite that employs supervised machine learning to
predict the druggability of a given protein. Benchmarking calculations against the Non-Redundant data set of Druggable and
Less Druggable binding sites demonstrate that an AUC for druggability prediction with eFindSite is as high as 0.88. With
eFindSite, we elucidated the human druggability space to be 10,191 proteins. Considering the disease space from the Open
Targets Platform and excluding already known targets from the predicted data set reveal 2731 potentially novel therapeutic
targets. eFindSite is freely available as a stand-alone software at https://github.com/michal-brylinski/efindsite.
Keywords Druggability prediction · Human proteome · Drug targets · Pocket prediction · Structural bioinformatics ·
Molecular modeling · eFindSite

Introduction
Pharmacology exploits the ability of bioactive compounds to
bind with a sufficient specificity to macromolecular targets
modulating their functions. New pharmaceuticals are developed through the onerous and often expensive process of
drug discovery. In 2010 the overall cost of developing a drug
and bringing it to market was estimated at 1–2 billion dollars
with a 14-year cycle [1]. In 2016, research done by the Tufts
Center for the Study of Drug Development put the cost of
bringing a drug to market at $2.6 billion with nearly 11.3%
of drugs that enter clinical testing being ever be approved
in the United States [2]. This is down from 16.4% of drugs
in 2005 [3]. Therefore, technology must be developed to
increase accuracy and precision in order to reduce costs
and miss-rates in drug discovery. It should be emphasized
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that most known proteins binding small molecules have no
known confirmed therapeutic effect. Although the ChEMBL
database comprises around 5000 known proteins with bindable pockets [4], only around 700 of these proteins are
confirmed therapeutic targets for FDA approved drugs [5].
Consequently, the candidacy of a protein, and thus a protein
pocket, for drug discovery is incredibly hard to confirm.
A large portion of the cost of drug development is due
to developmental failures. It is estimated that nearly 60%
of drug discovery failures are due to invalid or inappropriate identification of drug targets [6]. This is in part
due to the large discovery space of possible drug-protein
interactions. The total chemical space of drug discovery
is estimated to be 1 060 possible compounds [7], which can
be alleviated somewhat with chemical fragment libraries
and physiochemical thresholds reducing this number to
roughly 1023 possible drugs [8]. Drug discovery is further
complicated by the large number of possible protein targets
for therapeutics in humans. Estimates put the portion of
the human proteome related to some disease pathology at
10% [9, 10]. According to the Open Targets Platform this
number appears as a conservative estimate because nearly
25,000 human proteins are within the top 5th percentile of

13

Vol.:(0123456789)

510

disease association scores [11]. With these challenges, it
can be concluded that the validation of drug targets in an
experimental setting is logistically intensive.
In drug discovery, the analysis of a protein druggability is integral to successful target validation. Druggability, termed over 15 years ago [10], is currently defined as
the ability of a protein to be modulated by small druglike molecules, defined by Lipinski’s Rule of Five [12],
with sufficient affinity and specificity in vivo to create a
therapeutic effect in a relevant cellular pathway [1]. Traditionally, druggability was analyzed by co-crystalizing
proteins with organic solvents to expose possible hydrophobic pockets [13]. This approach eventually evolved to
the use of high-throughput screens and nuclear magnetic
resonance (NMR) analysis of chemical fragment libraries
[14]. In turn, hit rates were used as a metric for protein
druggability. However, these methods were problematic
as they had low sensitivity and high protein consumption
[15]. Recent approaches such as fragment-based NMR fluorescence assays work to overcome these problems [16].
Despite advancements in NMR spectroscopy, experimental
methods are still problematic in that their accuracies are
directly linked to the fragment library being used. Negative results from drug targets are generally inconclusive
and can only be controlled for using more complex and
diverse libraries. The same problem extends to reproducibility as the results of these tests are not normalized across
fragmentation libraries [17]. In response, the wide availability of pharmacologically relevant data sets has allowed
many groups to turn to computationally driven solutions
to assessing druggability.
In silico analysis of druggability starts with building models of drug binding pockets. Pocket prediction of in the past
has heavily relied on the high-resolution structural data from
X-ray crystallography and NMR spectroscopy. The effort
and time needed to produce such data is non-trivial even
with new methods emerging such as cryo-Electron Microscopy (cryo-EM). Even among known drug targets, a portion
of the proteome heavily overrepresented in structural biology, only half of the structures have been elucidated [18].
To overcome the lack of high-resolution data, researchers
have started turning to sequence-based homology modeling
to develop accurate protein pocket and ligand prediction
software. Homology modeling has a discrete advantage in
that nearly 95% of known drug targets are represented by an
acceptable homolog thus increasing the overall coverage of
pharmacologically relevant protein structures [18]. In this
paper, eFindSite [19, 20] is used to develop a new druggability classifier. eFindSite employs meta-threading to detect
weakly homologous templates, clustering techniques, supervised and unsupervised machine learning, and a confidence
estimation system to accurately predict drug-binding pockets
in protein structures. eFindSite thus provides a convenient
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means of pocket detection that can reliably analyze the protein without the need of high-resolution data.
Many druggability classifiers rely on the use of geometric and physiochemical descriptors to predict protein pocket
druggability. Geometric descriptors involve the size and
complexity of the cavity with the hypothesis that they are
directly correlated with easier drug binding and thus higher
druggability. However, these descriptors are heavily dependent on the structural information from the pocket prediction
algorithm being used. Thus, there is usually weak correlation between different data sets involving these descriptors.
Unlike geometric descriptors, however, the significance of
physiochemical descriptors of the pocket have been found
to be generally independent of the accuracy of the pocket
prediction algorithm [21]. Typically, druggability models
look for closed hydrophobic pockets within a protein target. These models lean on the knowledge that electrostatic
interactions between the ligand and the drug are in opposition to the desolvation energies. In a low dielectric medium
such as one exemplified by a lipophilic pocket, the electrostatic interactions are heightened in a quantifiable way [22].
Thus, hydrophobicity as described by [23] is a prominent
feature in assessing druggability. Due to these effects, it has
been hypothesized that polar residues matter significantly
in context specific instances as they often act as hydrogen
bond donors in drug-target interactions [22]. Another physiochemical characteristic of note is aromaticity, especially
in the case of tyrosine and tryptophan residues. Aromatic
amino acids have been hypothesized to interact with drugs
using cation-π bonding and π-stacking. In the case of tyrosine and tryptophan, the NE1 and OH groups act to enrich
the environment of the pocket with hydrogen bonds [24].
In this paper, we present a method to detect druggability of a pocket that conforms to previous physiochemical
findings. A machine learning classifier is developed using
descriptors from pocket prediction parameters calculated in
eFindSite and the characteristics of the active residues of the
pocket. Thus, the model is fully embedded into eFindSite
to create an all-in-one software for pocket prediction and
analysis. Finally, an inspection of the human proteome with
eFindSite was done to quantify a portion of feasibly druggable proteins. This is done in hopes to illuminating novel
classes of druggable targets that have yet been explored by
scientists either due to a lack of existing structural data, or
due to the large nature of the drug target space in humans.

Methods
Druggability data set
Training machine learning requires training data for the
algorithm to analyze and adapt from. The Non-Redundant
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data set of Druggable and Less Druggable binding sites
(NRDLD) provides us with a wholistic analysis on the druggability of over 130 known proteins [25]. This data set, however, lacks proper resolution for our research since it does
not specify polypeptide chains of the proteins. To account
for heteropolymers, each of the 198 protein chains had their
pockets manually analyzed using VMD [26] for druggable
ligands. Pockets are labeled as druggable or less druggable
based on whether their ligand structures match any known
drugs followed by cross referencing against the PDB [27].
The ligands are matched to each pocket using the pocket
with the shortest Euclidean distance between the geometric
center of the pocket and the geometric center of the ligand.
A curated druggability data set with polypeptide chain resolution along with protein pocket ligands confirming pocket
druggability is compiled. A threshold of 6 Å Euclidean distance between the pocket center predicted by eFindSite and
the geometric center of a ligand is used to make sure that
accurately predicted pockets are used in the training set. This
modified data set of 240 predicted pockets in 181 polypeptide chains is used to train druggability classifiers.

Feature selection
Two types of descriptors are considered when analyzing
possible feature candidates in druggability elucidation. Protein pocket predictors are hypothesized to have an extended
application in druggability prediction. Table 1 lists seven
pocket descriptors computed by eFindSite chosen as possible feature candidates, including the fraction of templates assigned to a particular pocket (temp_frac), the log
of the absolute number of templates assigned to a pocket
(temp_log), the average Template Modeling score [28] of the
templates to a target (TM-score), the average confidence of
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binding residues (res_conf), the log of the number of binding
residues (res_log), the Protein–Ligand Binding index (PLB_
index) [29], and the pocket confidence score (pock_conf).
eFindSite software predicts the relevant residues within
the protein pocket and thus physiochemical properties of
these binding residues are analyzed as possible druggability feature candidates [19]. Based on findings of previous
druggability prediction software, including DrugPred [25]
and PockDrug [21], hydropathy, weighted frequency of
polar residues (polar_freq), weighted frequency of aromatic
residues (aromatic_freq), and frequency of tyrosine atoms
(tyr_freq) are included in parameter analysis (Table 1). All
frequencies are weighted using confidence estimates calculated by eFindSite.
After the candidates are chosen, violin plots are calculated for the NRDLD druggability data set in order to visualize the distributions of each of the 11 features in druggable
and non-druggable proteins. To quantify the correlations
and to exclude the possibility of randomness accounting for
these correlations, the Monte-Carlo variant of the FischerPittman permutation test is applied via a permute python
module [30]. The data set is resampled 100,000 times without replacement to calculate p-values. Any feature with a
p-value > 0.02 is discarded from the druggability classifier.

Prediction models
The druggability data set, while reflecting a great deal of
research, is relatively small sample size to work with statistically. In choosing the machine learning algorithms, rather
than select more popular machine learning models such as
neural networks, support vector machines, and random forest
techniques, a more basic approach is taken using graphical
machine learning models in order to reduce the possibility

Table 1  Description and analysis of relevant investigated descriptors
Descriptor

Description of the descriptor

Difference of means

p-value

temp_frac
temp_log
TM-score
res_conf
res_log
PLBI
pock_conf
aromatic_freq
tyr_freq
polar_freq

Fraction of templates assigned to a pocket by eFindSite
Log of the absolute number of templates assigned to a pocket by eFindSite
Average template modeling score of the templates to a target
Average confidence of binding residues predicted by eFindSite
Log of the number of binding residues predicted by eFindSite
Protein–ligand binding index
Pocket confidence calculated by eFindSite
Weighted frequency of predicted binding aromatic residues (H, F, Y, W)
Weighted frequency of predicted binding tyrosine residues (Y)
Weighted frequency of predicted binding polar residues (C, D, E, H, K, N, Q, R,
S, T, W, Y)
Average weighted hydropathy of predicted binding residues

0.278
1.85
0.0176
0.00842
0.468
0.0592
0.0241
0.755
0.183
0.438

Near 0
Near 0
0.123
0.807
Near 0
0.0161
0.00959
Near 0
0.00876
0.0633

1.21

Near 0

hydropathy

All descriptors are computed with eFindSite. p-Values and mean differences between druggable and non-druggable classes are calculated with
the Fisher-Pittman permutation test
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of overfitting. The two models settled on are logistic regression (LR) and linear discriminant analysis (LDA). A weight
vector is calculated via the scikit-learn module [31] for
LDA, and the Newton–Raphson method [32] is used for the
dichotomous case of LR. Since the Newton Raphson and
LDA both require matrix inversions, using all nine pocket
descriptors is too unstable for the algorithm. Thus, two sets
of parameters are used to create two different classifiers
for LDA and LR with different sets of pocket descriptors
employed developed to elucidate druggability.

Model evaluation
Classifiers are evaluated using the Receiver Operating Characteristic (ROC) analysis. ROC displays in a plot the fall-out,
or false-positive rate (FPR), i.e. the inability to recognize
non-druggable pockets, against the sensitivity, or true-positive rate (TPR), i.e. the capacity to correctly identify druggable binding sites. The area under the ROC curve (AUC)
is calculated and compared amongst models to establish the
default model to be implemented into eFindSite. The confidence intervals of the AUC are estimated non-parametrically
by bootstrapping 100,000 times. A 10-fold cross validation
is used to confirm the viability of a machine learning model.
To optimize threshold values, the Mathew Correlation Coefficient (MCC) [33] is calculated over all possible thresholds
between 0 and 1. A model with the highest AUC is used
to measure performance against Fpocket, a popular pocket
druggability prediction tool with over 250 downloads in the
past year alone [34]. This is done using one pocket from
each of the 198 polypeptide chains in the NRDLD data set.
The model is also independently evaluated for sensitivity on
the scPDB data set, a collection of solely druggable proteins
across multiple proteomes [35]. The ligands for these proteins have their predicted pockets matched to eFindSite in a
manner identical to that of the NRDLD data set. The scPDB
data set comprises 15,298 druggable pockets.

Annotated structural human proteome
The structural human proteome is constructed using a reference genome, GRCh38 (Genome Reference Consortium
Human Build 38), from the Human genome project [36]
downloaded from the Ensembl database [37]. The entire
annotated data set comprises 89,872 sequences 50–999
amino acids in length. The 3D structures of these gene products are built with eThread [38] followed by a quality assessment with ModelEvaluator [39] in terms of the estimated
Global Distance Test (GDT_TS) score [40]. Subsequently,
ligand-binding pockets are predicted in confidently modeled
target structures with eFindSite [19]. The top-ranked pockets
are subject to fingerprint-based virtual screening [20] against
a non-redundant subset of 244,659 small molecules selected
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from the ZINC library [41]. The druggability of each protein is assessed using the default classifier from eFindSite.
The disease space of the human proteome is estimated by
mapping gene products to the Open Targets Platform [11],
a set of known proteins with significant association to a disease. Those genes with a disease association score of ≥ 0.5
are considered relevant, and any protein expressed from a
relevant gene is considered linked, in part, to some disease.
Finally, known drug targets in the human proteome are identified by mapping the sequences of gene products to drug
targets in DrugBank [42]. Those polypeptides having at least
one protein in DrugBank with a sequence identity of ≥ 80%
are labelled as known drug targets.

Results and discussion
Binary classifier for pocket druggability
Of the 11 pocket descriptors scrutinized in this study,
Table 1 shows that only eight pass the stringent requirement
of p-values ≤ 0.02. Five of these descriptors are related to
protein pocket prediction, whereas the other three are physiochemical descriptors. The analysis of the distributions of
these descriptors is presented in Fig. 1. Due to the unstable
nature of computing matrix inversions, the descriptors were
organized into two different models. Table 2 shows that the
first model (Model 1) introduces a stringent requirement of
using descriptors with p-value ≤ 0.001, while the second
model (Model 2) uses mainly protein pocket prediction
descriptors along with hydropathy. Despite the prevalence
of polar attributes in other models [22], the polar_freq value
was not statistically relevant to be included in the model.
Thus, current models reflect closed “greasy” pockets as the
ideal druggable sites.
The performances of each of the two LR and LDA models
developed in this study are tested on a training data set of
240 protein pockets. Figure 2a shows ROC plots graphed
for each of the four classifiers with the AUC of each classifier used to determine its accuracy. The AUC of Model 1 is
0.910 for LR (LR-1) and 0.898 for LDA (LDA-1), whereas
the AUC of Model 2 is 0.901 for LR (LR-2) and 0.909 for
LDA (LDA-2). The model with the numerically largest AUC
(LR-1) is selected as the default classifier for eFindSite. Figure 2b shows that the maximum MCC values of individual
models range from 0.6 to 0.7. The default model yields the
highest MCC of 0.702 at a probability threshold of 0.732.
Fpocket is one of the most widely used protein pocket
prediction programs [34]. Due to its geometric approach
to modeling pockets and inclusion of relevant polar
parameters, Fpocket is the perfect subject of comparison
to test the performance of eFindSite. The analysis of all
pockets in the NRDLD data set determines AUC values
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Fig. 1  Violin plots for statistically relevant pocket descriptors. The
horizontal blue bar represents the mean, whereas the horizontal purple bar represents the median of a particular data set. The following
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descriptors are analyzed: a temp_frac, b temp_log, c res_log, d PLB_
index, e pock_conf, f hydropathy, g tyr_freq, and h aromatic_freq

Sensitivity validation on the scPDB data set
Table 2  Organization of
statistically relevant pocket
descriptors

Descriptor

Model used in

temp_frac
temp_log
res_log
PLB_index
pock_conf
hydropathy
tyr_freq
aromatic_freq

1, 2
1, 2
1, 2
2
2
1, 2
–
1

tyr_freq was not used due to
inability to meet the p-value
≤ 0.001 requirement of Model
1 and because it was already
generalized in aromatic_freq in
Model 2

of 0.882 for eFindSite and 0.794 for Fpocket with the corresponding ROC graphs shown in Fig. 3a. Furthermore,
0.95 confidence intervals are 0.845–0.928 for eFindSite
and 0.752–0.871 for Fpocket (Fig. 3b). Thus, there is a
quantifiable increase in performance from Fpocket to
eFindSite.

Sensitivity of the model was independently tested on the
scPDB data set. Figure 4 shows that of 15,298 druggable
pockets in this set, 9376 pockets are predicted with a high
confidence of ≥ 0.8 (solid orange line). Furthermore, the
MCC calculated for predicted binding residues is ≥ 0.4 for
12,411 pockets (solid blue line). Encouragingly, as many as
9575 pockets (62.6%) are correctly classified by eFindSite
as druggable (solid green line). We may expect the sensitivity accuracy to increase when only confidently and accurately predicted pockets are considered. Indeed, of 9376
confidently predicted pockets, 7667 (81.8%) are classified
as druggable (dotted-dashed green line), whereas of 8119
confidently predicted pockets whose MCC is ≥ 0.4, 6727
(82.9%) are classified as druggable (dotted green line). This
analysis demonstrates that the sensitivity of druggability
prediction with eFindSite is quite high and the majority of
confidently identified pockets are in fact druggable.
Next, we selected a subset of 101 scPDB proteins
whose structures were deposited into the PDB after July
2016 and conducted druggability prediction by eFindSite
with a template library constructed from the June 2016
snapshot of the PDB. Figure 5 demonstrates that the performance of eFindSite using a library compiled before
the structure of any of target proteins was determined
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Fig. 2  Assessment of the performance of draggability classifiers. a
ROC plots and b MCC for varying threshold values. Four classifiers
are evaluated, LR-1 (Model 1), LR-2 (Model 2), LDA-1 (Model 1),

and LDA-2 (Model 2). TPR is the true positive rate and FPR is the
false positive rate. Gray regions represent the performance of a random classifier

Fig. 3  Performance comparison of eFindSite and Fpocket. This
evaluation is conducted against all 198 polypeptides in the curated
NRDLD data set. a ROC plots for druggability prediction with eFindSite and Fpocket. TPR is the true positive rate and FPR is the false

positive rate. A gray region represents the performance of a random
classifier. b Histogram of bootstrapped distributions of randomly resampled AUC scores

experimentally is only slightly lower than that obtained
in February 2017. Indeed, the median druggability values are 0.823 for June 2016 and 0.854 for February 2017
template libraries. Thus, eFindSite is able to function as
a prospective predictor.

Druggable pockets in the human proteome
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An analysis of druggability is performed on the structural human proteome from the curated GRCh38 data set.
Figure 6 shows that 63,713 (70.9%) structure models are
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Fig. 4  Performance of eFindSite against the scPDB data set. Histogram of the pocket confidence by eFindSite, the MCC calculated for
binding residues predicted by eFindSite, and the druggability calculated with LR-1 (Model 1). Solid lines represent the entire data set,
whereas dotted-dashed and dotted lines represent the data set filtered
by the pocket confidence and the MCC. Dashed lines mark thresholds
at which the data set was filtered

Fig. 5  Violin plots for the retrospective assessment of druggability
prediction. The druggability of 101 scPDB proteins, whose structures
were deposited into the PDB after July 2016, is predicted by eFindSite with template libraries constructed from June 2016 (purple) and
February 2017 (gold) snapshots of the PDB. The horizontal green bar
represents the mean, whereas the horizontal red bar represents the
median of a particular data set

confidently predicted with an GDT_TS score of at least 0.4
(solid purple line), of which 39,271 are annotated with putative binding sites by eFindSite. The data set is further pruned
for a ≥ 0.8 confidence of the top-ranked pocket resulting
in 16,203 (41.3%) proteins used to analyze the druggable
human proteome (solid orange line). The druggability of
each protein is assessed using the classifier from eFindSite
with a probability threshold of ≥ 0.5. From the data set,
10,191 (62.9%) proteins are found to be druggable with high
confidence (dotted-dashed green lines).
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Fig. 6  Inspection of protein druggability across the human proteome.
Histogram of the structure confidence assessed with model GDT_TS
by eThread, the pocket confidence by eFindSite, and the druggability
calculated with LR-1 (Model 1). Solid lines represent the entire data
set, whereas dotted-dashed line represents the data set filtered by the
pocket confidence. Dashed lines mark thresholds at which the data set
was filtered

Fig. 7  Analysis of relevant drug targets in the human proteome. The
disease space corresponds to those human gene products having a
disease association score of ≥ 0.5. Known targets are proteins within
the confidently classified data set (GDT_TS by eThread of ≥ 0.4
and the pocket confidence by eFindSite of ≥ 0.8) that have a close
homolog in DrugBank (sequence identity of ≥ 0.8). Predicted targets
are proteins within the confidently classified data set with a druggability score by eFindSite of ≥ 0.5. The set of all proteins within the
disease space and the predicted target space, but not in the known target space are considered relevant novel targets

Analysis of proteins expressed from probable gene disease candidates and known drug targets is conducted to
discern relevant proteins for study. Figure 7 shows that the
disease space of the human proteome comprises 45,766 gene
products (blue circle), whereas 13,412 proteins are known
drug targets (red circle). As expected, there is a significant
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overlap between the disease space and known targets comprising 9357 proteins. Out of 10,191 gene products predicted
by eFindSite to be druggable (Fig. 7, green circle), 3867
are already known drug targets, whereas 3593 are outside
the disease space according to the Open Targets Platform.
Interestingly, as many as 2731 proteins within the predicted
druggability space are expressed from genes with disease
association scores of ≥ 0.5, yet are not catalogued in DrugBank. These proteins are potentially novel targets that can
be exploited for drug discovery.
Case study: α/β hydrolase domain‑containing protein 11
Below, we discuss a couple of representative cases selected
from the predicted druggable human proteome. Note that
neither these proteins nor their close homologs are included
in the DrugBank database combining detailed drug data with
the comprehensive information on 4985 non-redundant drug
targets [42]. The first example is α/β hydrolase domain-containing protein 11 (ABHD11) comprising 315 amino acid
residues. A 3D model of ABHD11 was constructed based
on the X-ray structure of haloalkane dehalogenase from
Xanthobacter autotrophicus (PDB-ID: 2yxp, chain A) [43].
Although both proteins share only 26.3% sequence identity, the estimated GDT_TS score for the ABHD11 model
is as high as 0.70. Figure 8a shows the top-ranked pocket
(gold) predicted by eFindSite with a 97.4% confidence in
the structure model (purple). This binding site comprising
17 residues (H73, G74, L75, F76, F77, H140, S141, M142,
F177, Y180, V181, M184, L201, W232, F270, H296, and
W297) is assigned a high druggability of 0.98 by the default,
LR-1 model.

Fig. 8  Druggability assessment of α/β hydrolase domain-containing
protein 11 (ABHD11). a Structure model of ABHD11 (solid purple
cartoons) with a putative, druggable pocket (a transparent gold surface). Predicted binding residues are shown as solid sticks and the
shiny gold sphere is the pocket center. Models of ABHD11 com-
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Next, we docked two top-ranked compounds identified
by fingerprint-based virtual screening in the ZINC library
into the binding site of ABHD11 with eSimDock [44].
The resulting models of ABHD11-ZINC63536302 and
ABHD11-ZINC70638822 are shown in Fig. 8b, c, respectively. eSimDock is a similarity-based docking approach
that places ligands within the predicted binding sites by
superposing them onto ligand-bound templates. It selected
the alpha-amino acid ester hydrolase from Acetobacter turbidansand complexed with d-phenylglycine (PDB-ID: 2b4k,
chain A, ligand PG9) [45] as a template for the ABHD11ZINC63536302 model and the human soluble epoxide
hydrolase complexed with an inhibitor (PDB-ID: 5all, chain
A, ligand II6) [46] for the ABHD11-ZINC70638822 model.
Not only are both template proteins structurally similar to
ABHD11 with a TM-score of 0.72 (2b4k) and 0.79 (5all),
but their bound ligands are also chemically similar to both
ZINC compounds with a Tanimoto coefficient (TC) [47]
reported by kcombu [48] of 0.39 (PG9 and ZINC63536302)
and 0.50 (II6 and ZINC70638822).
An analysis of binding poses of ZINC molecules within
the pocket of ABHD11 carried out with the eAromatic
program [49] reveals a network of aromatic interactions
with the side-chains of Y180, F270, H296, F177, and
W297. Moreover, the Ligand Protein Contact (LPC) software [50] reports hydrophobic interactions between the
cyclohexoxyl (ZINC63536302) and the 4-hydroxytetrahydropyran (ZINC70638822) moieties, and a cluster of nonpolar residues, A202, L206, V209, V215. It is important to
note that both compounds selected from the ZINC library
by virtual screening closely match the physicochemical
parameters of putative binders of ABHD11 estimated by
eFindSite, a molecular weight (MW) of 247.0 Da ± 147.5,

plexed with top-ranked compounds identified with virtual screening:
b ZINC63536302 and c ZINC70638822. Small molecules are colored
by atom type, relevant pocket residues are represented by solid gold
sticks, and target structure is shown in transparent purple

Journal of Computer-Aided Molecular Design (2019) 33:509–519

an octanol–water partition coefficient (logP) of 1.17 ± 2.48,
and a polar surface area (PSA) of 78.8 Å2 ± 58.8. The MW,
logP, and PSA are, respectively, 291.2 Da, 3.18, and 58.6
Å2 for ZINC63536302, and 263.2 Da, 1.97, and 58.6 Å2 for
ZINC70638822.
Case study: 5‑aminolevulinic acid synthase 2
Another example of a confidently predicted druggable binding pocket in the human proteome is a putative pyridoxal
5′-phosphate site of erythroid specific mitochondrial 5-aminolevulinate synthase (ALAS2) comprising 587 amino acid
residues. Figure 9a shows a 3D model of ALAS2 (purple)
constructed based on the X-ray structure of serine palmitoyltransferase from Sphingobacterium multivorum (PDB-ID:
3a2B, chain A) [51]. This model exhibits a modest estimated
GDT-score of 0.56 with the 31.6% target-template sequence
identity. Figure 9a also shows the top-ranked pocket (gold)
predicted by eFindSite with 87.8% confidence comprising
10 residues (C258, F259, H285, A286, S287, H331, S332,
V359, H360, and K391). This binding site is assigned a
druggability of 0.77 by the LR-1 model.
Next, two top-ranked compounds identified by fingerprint-based screening were docked into the binding site
of ABHD11 with eSimDock. The constructed models of
ALAS2-ZINC00517451 and ALAS2-ZINC00169159 are
shown in Fig. 9b, c, respectively. eSimDock selected methionine γ-lyase complexed with β-butenoic acid-pyridoxal5′-phosphate from Entamoeba histolytica (PDB-ID: 3ael,
chain A, ligand 4LM) [52] as the template for both ALAS2ZINC00517451 and ALAS2-ZINC00169159 models. The
template protein has a moderate structure similarity to
ALAS2 with a TM-score of 0.46, however, the probability that it shares a pocket with ALAS2 is 0.71. The TC

Fig. 9  Druggability assessment of 5-aminolevulinic acid synthase 2
(ALAS2). a Structure model of ALAS2 (solid purple cartoons) with
a putative, druggable pocket (a transparent gold surface). Predicted
binding residues are shown as solid sticks and the shiny gold sphere
is the pocket center. Models of ALAS2 complexed with top-ranked
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values are 0.66 for 4LM-ZINC00517451 and 0.47 for 4LMZINC00169159, indicating sufficiently high chemical similarity to construct reliable template-based complex models.
An analysis with eAromatic shows an aromatic residue,
H285, forming parallel stacking with both ligands, whereas
LPC reveals hydrophobic interactions between the pyridinyl N1 moiety, and H285 and V359 residues. Further,
both compounds selected from the ZINC library by virtual
screening have physicochemical parameters similar to the
putative binders of ALAS2 estimated by eFindSite: an MW
of 254.0 Da ± 123.0, a logP of 0.51 ± 1.14, and a PSA of
122.4 Å2 ± 62.4. The MW, logP, and PSA are, respectively,
167.2 Da, 0.89, and 42 Å2 for ZINC00517451, and 167.2 Da,
1.31, and 42 Å2 for ZINC00169159.

Conclusion
Identification of suitable targets for pharmacotherapy in the
human proteome is a critical component of drug development. To improve the state-of-the-art in drug target identification, a new pocket druggability prediction algorithm
was developed and implemented in eFindSite. Protein pocket
predictors are shown in this study to be generalized to the
prediction of pocket druggability. Although certain physiochemical predictors such as the hydropathy and the aromatic
character of pocket residues are found to be statistically relevant in the analysis of pocket druggability with current data
sets, the pocket polarity is not statistically correlated with
druggability. Consequently, the current algorithm favors
closed, “greasy” pockets as druggable binding sites.
Subsequently, the extended eFindSite is used to analyze
the scope of the druggable human proteome. Our findings
indicate that druggable targets make up about 7% of the

compounds identified with virtual screening: b ZINC00517451 and c
ZINC00169159. Small molecules are colored by atom type, relevant
pocket residues are represented by solid gold sticks, and target structure is shown in transparent purple
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human proteome. As more data are accumulated, the estimated number of druggable proteins is likely to increase.
eFindSite is freely available as a stand-alone software at
https://github.com/michal-brylinski/efindsite.
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